SCHEMBL580658

SCHEMBL580658

CC(C)(C)OC(=O)n1ccc2c(Cl)ccnc21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP3 O14638 3/20 0.48
ENPP1 P22413 3/20 0.48
HSP90AA1 P07900 1/20 0.39
HSP90AB1 P08238 1/20 0.39
POLB P06746 1/20 0.39
BUB1 O43683 1/20 0.38
NOTUM Q6P988 2/20 0.36
ELANE P08246 1/20 0.36
SLC22A12 Q96S37 1/20 0.35
ATR Q13535 1/20 0.35
BCHE P06276 1/20 0.35
FGFR1 P11362 1/20 0.34
FGFR4 P22455 1/20 0.34
PIK3CD O00329 1/20 0.34
ABL1 P00519 1/20 0.34
EGFR P00533 1/20 0.34
HCK P08631 1/20 0.34
SRC P12931 1/20 0.34
KDR P35968 1/20 0.34
PIK3CA P42336 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31240726 1.00 ENPP3 (0.48) ENPP3ENPP1HSP90AA1HSP90AB1POLB
SCHEMBL24319665 0.84 BUB1 (0.39) ENPP3ENPP1HSP90AA1HSP90AB1POLB
SCHEMBL29128021 0.84 BUB1 (0.39) ENPP3ENPP1HSP90AA1HSP90AB1POLB
SCHEMBL25703228 0.83 BUB1 (0.38) ENPP3ENPP1HSP90AA1HSP90AB1POLB
SCHEMBL29522590 0.83 PIK3CA (0.38) ENPP3ENPP1HSP90AA1HSP90AB1POLB
SCHEMBL2792837 0.83 HSP90AA1 (0.39) ENPP3ENPP1HSP90AA1HSP90AB1POLB
SCHEMBL138212 0.83 PIK3CA (0.38) ENPP3ENPP1HSP90AA1HSP90AB1POLB
SCHEMBL30991728 0.83 BUB1 (0.38) ENPP3ENPP1HSP90AA1HSP90AB1POLB
SCHEMBL31330402 0.83 HSP90AA1 (0.37) ENPP3ENPP1HSP90AA1HSP90AB1POLB
SCHEMBL1457357 0.83 HSP90AA1 (0.37) ENPP3ENPP1HSP90AA1HSP90AB1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200247812-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE INTEGRAL BIOSCIENCES PRIVATE LTD (IN) 2020-08-06 US disclosed
US-20200247812-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE INTEGRAL BIOSCIENCES PRIVATE LTD (IN) 2020-08-06 US disclosed
WO-2020012357-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE INTEGRAL BIOSCIENCES PVT. LTD. (IN) 2020-01-16 WO disclosed
WO-2020012357-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE INTEGRAL BIOSCIENCES PVT. LTD. (IN) 2020-01-16 WO disclosed
US-9242961-B2 Aurora kinase modulators and method of use AMGEN INC. (US) 2016-01-26 US disclosed
US-9242961-B2 Aurora kinase modulators and method of use AMGEN INC. (US) 2016-01-26 US disclosed
US-9242961-B2 Aurora kinase modulators and method of use AMGEN INC. (US) 2016-01-26 US disclosed
EP-1984353-B1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC (US) 2015-12-30 EP disclosed
EP-1984353-B1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC (US) 2015-12-30 EP disclosed
EP-2418209-B1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC (US) 2014-06-25 EP disclosed
US-7560551-B2 Aurora kinase modulators and method of use AMGEN INC. (US) 2009-07-14 US disclosed
US-20090163501-A1 Aurora kinase modulators and method of use AMGEN INC. (US) 2009-06-25 US disclosed
US-20090163501-A1 Aurora kinase modulators and method of use AMGEN INC. (US) 2009-06-25 US disclosed
US-20090163501-A1 Aurora kinase modulators and method of use AMGEN INC. (US) 2009-06-25 US disclosed
EP-1984353-A1 AURORA KINASE MODULATORS AND METHOD OF USE Amgen, Inc (US) 2008-10-29 EP disclosed
US-20070185111-A1 Aurora kinase modulators and method of use AMGEN INC. 2007-08-09 US disclosed
US-20070185111-A1 Aurora kinase modulators and method of use AMGEN INC. 2007-08-09 US disclosed
US-20070185111-A1 Aurora kinase modulators and method of use AMGEN INC. 2007-08-09 US disclosed
WO-2007087276-A1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC. (US) 2007-08-02 WO disclosed
WO-2007087276-A1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC. (US) 2007-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185111-A1 Aurora kinase modulators and method of use AURKC, AURKA, CDK1 ENPP3 1651/4885ENPP1 1130/4885HSP90AA1 2278/4885
US-20090163501-A1 Aurora kinase modulators and method of use AURKC, AURKA, AURKB ENPP3 1771/4885ENPP1 1575/4885HSP90AA1 3421/4885
US-20200247812-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE ACVR1, ACVRL1, ALK ENPP3 548/4885ENPP1 243/4885HSP90AA1 3002/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.